FDA already may be nearing the peak of its ability to approve applications during the first review cycle, less than a year into use of a new review system intended for that purpose.
The agency’s first-cycle approval rate, which measures the portion of submitted applications successfully cleared before their first user fee goal date, is so high now that FDA is wondering whether...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?